Fig. 1 | British Journal of Cancer

Fig. 1

From: Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Fig. 1

Pharmacokinetics of CFI-400945. Plasma concentration of CFI-400945 as a function of time and dose level following dosing on Cycle 1 day 1 (a). Cmax (b) and AUC (c) as a function of dose level following dosing on day 1 are also shown. Shapes represented in black (b/c) indicate patients experiencing grade 3 or 4 neutropenia at various dose levels Cmax concentration maximum. AUC area under the curve

Back to article page